Heart failure with preserved ejection fraction (HFpEF) is present in nearly half of patients with heart failure. The prevalence of heart failure with normal or near-normal ejection fractions increases more rapidly than in patients with reduced ejection fractions. Angiotensin-converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), aldosterone antagonist, β-blocker, and calcium channel blocker have not shown significant efficacy in HFpEF clinical trials. Sacubitril/Valsartan, combined angiotensin receptor blocker (Valsartan) with neprilysin inhibitor (Sacubitril), was the first-of-its-kind angiotensin receptor-neprilysin inhibitor (ARNI) to be developed. It has shown significant efficacy on HFpEF in recent studies. It is considered that most of the current Sacubitril/Valsartan studies are still concentrated in the field of heart failure, especially heart failure with reduced ejection fraction (HFrEF). This review discusses the latest advances in cardiovascular, renal, and metabolic aspects of Sacubitril/Valsartan, mainly in HFpEF, providing more evidence for further future research on Sacubitril/Valsartan and raising issues that should be paid attention. At the same time, this review will introduce the academic consensus on Sacubitril/Valsartan in treating HFpEF in China.

近一半的心力衰竭患者存在射血分数保留的心力衰竭 (HFpEF)。射血分数正常或接近正常的心力衰竭患病率比射血分数降低的患者增加得更快。血管紧张素转换酶抑制剂 (ACEI)、血管紧张素受体阻滞剂 (ARB)、醛固酮拮抗剂、β 受体阻滞剂和钙通道阻滞剂在 HFpEF 临床试验中未显示出显着疗效。Sacubitril/Valsartan 是血管紧张素受体阻滞剂 (Valsartan) 与脑啡肽酶抑制剂 (Sacubitril) 的联合用药，是首个待开发的血管紧张素受体脑啡肽酶抑制剂 (ARNI)。在最近的研究中，它已显示出对 HFpEF 的显着疗效。认为目前大多数沙库巴曲/缬沙坦的研究仍集中在心力衰竭领域，尤其是射血分数降低的心力衰竭（HFrEF）。本综述讨论了沙库巴曲/缬沙坦在心血管、肾脏和代谢方面的最新进展，主要是在HFpEF中，为进一步研究沙库巴曲/缬沙坦提供了更多证据，并提出了应注意的问题。同时，本综述将介绍我国对沙库巴曲/缬沙坦治疗HFpEF的学术共识。为沙库巴曲/缬沙坦的进一步研究提供更多证据，提出应注意的问题。同时，本综述将介绍我国对沙库巴曲/缬沙坦治疗HFpEF的学术共识。为沙库巴曲/缬沙坦的进一步研究提供更多证据，提出应注意的问题。同时，本综述将介绍我国对沙库巴曲/缬沙坦治疗HFpEF的学术共识。